首都医科大学学报 ›› 2022, Vol. 43 ›› Issue (5): 713-719.doi: 10.3969/j.issn.1006-7795.2022.05.008

• 肾脏病基础与临床研究 • 上一篇    下一篇

IgA肾病国际风险预测工具在中国人群中的预测效果评价

郭康林, 程一春, 葛树旺, 徐钢*   

  1. 华中科技大学附属同济医院肾脏内科,武汉430030
  • 收稿日期:2022-05-09 出版日期:2022-10-21 发布日期:2022-10-25

External validation of the international IgA nephropathy prediction tool in a modern Chinese cohort

Guo Kanglin, Cheng Yichun, Ge Shuwang, Xu Gang*   

  1. Department of Nephrology, Division of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
  • Received:2022-05-09 Online:2022-10-21 Published:2022-10-25
  • Contact: * E-mail:xugang@tjh.tjmu.edu.cn.

摘要: 目的 用一个现代中国人队列对IgA肾病国际风险预测工具进行了外部验证,为该工具的临床推广应用提供更多可靠的证据。方法 纳入2012年1月至2016年12月在华中科技大学附属同济医院行肾穿刺确诊的467例IgA肾病患者。以估计肾小球滤过率(estimated glomerular filtration rate,eGFR)下降超50%或终末期肾衰竭为终点事件,采用IgA肾病国际风险预测工具计算每个患者到达终点事件的概率,即为预测风险。从区分度、校准度、重新分类和临床效用等几个方面评估IgA肾病国际风险预测工具中2种模型(即不包含种族因素的模型1,包含种族因素的模型2)的表现。结果 本研究中,现代中国人队列的中位随访时间是4年,48(10%)人到达终点事件。2个模型的C指数均为0.86,且生存曲线分离良好,表现出优秀的区别能力。2个模型在校准方面表现也基本一致,均轻微低估了5年风险。重新分类表明,两个模型在预测5年风险方面无明显差别。决策曲线分析表明2个模型在预测5年风险方面具有临床实用性且无明显差异。结论 IgA肾病国际风险预测工具表现出了显著的区分性、可接受的校准度和满意的临床实用性,且2种模型无明显差异。

关键词: IgA肾病, 预后模型, 外部验证

Abstract: Objective To externally validate the international IgA nephropathy prediction tool in a modern Chinese cohort, so as to provide more evidence for clinical application. Methods This study included IgA nephropathy patients diagnosed by kidney puncture in Tongji Hospital Affiliated to Huazhong University of Science and Technology from January 2012 to December 2016. The predicted risk of each patient was calculated according to the international IgA nephropathy prediction tool, with the 50% decline of estimated glomerular filtration rate (eGFR) or end-stage renal failure as the endpoint. This study evaluated the performance of two models (Model 1: without racial factor; Model 2: with racial factor) in the international IgA nephropathy prediction tools in discrimination, calibration, reclassification and clinical utility. Results The median follow-up time in the modern Chinese cohort in this study was 4 years, and 48(10%) subjects reached the endpoint. The C indices of the two models were 0.86, and the survival curves were well separated, showing excellent discrimination ability. The performance of the two models in calibration is basically the same, both slightly underestimate the risk of 5 years. The reclassification indicates that there is no significant difference between the two models in predicting 5-year risks. The decision curves analysis showed that the two models were clinically practical in predicting five-year risks, and there was no significant difference between two models. Conclusion The international IgA nephropathy prediction tools showed significant discrimination, acceptable calibration and satisfactory clinical utility, and there is no significant difference between the two models.

Key words: IgA nephropathy, prognostic model, external validation

中图分类号: